Literature DB >> 6229255

Apolipoproteins (A-I, A-II, B), Lp(a) lipoprotein and lecithin: cholesterol acyltransferase activity in diabetes mellitus.

G Schernthaner, G M Kostner, H Dieplinger, R Prager, I Mühlhauser.   

Abstract

Concentrations of HDL cholesterol, apolipoprotein (apo) A-I and apo A-II were found to be significantly decreased in patients with insulin-dependent diabetes (IDD) and non-insulin-dependent diabetes (NIDD) compared with carefully selected controls matched for sex, age and body weight. LDL cholesterol and apo B levels did not differ significantly between diabetics and controls. Concentrations of lipoprotein Lp(a), an independent risk factor for coronary artery disease in non-diabetics, were above 20 mg/dl in only 14% of diabetics and in 5% of controls. LCAT activity was normal in diabetics, irrespective of type of diabetes, sex and age of patients. No correlation between HbA1 and either HDL cholesterol or A-I and A-II was found in IDD and NIDD. A positive correlation between HbA1 and either triglyceride or VLDL triglyceride was noted in IDD and NIDD. There was also a positive correlation between insulin dosage in IDD and HDL cholesterol, apolipoprotein A-I and A-II.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6229255     DOI: 10.1016/0021-9150(83)90139-9

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  19 in total

Review 1.  [Value of biguanide in therapy of diabetes mellitus].

Authors:  E Haupt; U Panten
Journal:  Med Klin (Munich)       Date:  1997-08-15

Review 2.  Lipoprotein alterations in diabetes mellitus.

Authors:  G M Kostner; I Karádi
Journal:  Diabetologia       Date:  1988-10       Impact factor: 10.122

3.  The impact of glycation on apolipoprotein A-I structure and its ability to activate lecithin:cholesterol acyltransferase.

Authors:  E Nobecourt; M J Davies; B E Brown; L K Curtiss; D J Bonnet; F Charlton; A S Januszewski; A J Jenkins; P J Barter; K-A Rye
Journal:  Diabetologia       Date:  2007-01-10       Impact factor: 10.122

Review 4.  Alterations in lipoprotein defense against oxidative stress in metabolic syndrome.

Authors:  Boris Hansel; Anatol Kontush; Dominique Bonnefont-Rousselot; Eric Bruckert; M John Chapman
Journal:  Curr Atheroscler Rep       Date:  2006-11       Impact factor: 5.113

5.  Plasma cholesterol metabolism in end-stage renal disease. Difference between treatment by hemodialysis or peritoneal dialysis.

Authors:  H Dieplinger; P Y Schoenfeld; C J Fielding
Journal:  J Clin Invest       Date:  1986-04       Impact factor: 14.808

6.  In search of a physiological function of lipoprotein(a): causality of elevated Lp(a) levels and reduced incidence of type 2 diabetes.

Authors:  Sotirios Tsimikas
Journal:  J Lipid Res       Date:  2018-04-02       Impact factor: 5.922

7.  Relationship of progressively increasing albuminuria to apoprotein(a) and blood pressure in type 2 (non-insulin-dependent) and type 1 (insulin-dependent) diabetic patients.

Authors:  G Jerums; T J Allen; C Tsalamandris; A Akdeniz; A Sinha; R Gilbert; M E Cooper
Journal:  Diabetologia       Date:  1993-10       Impact factor: 10.122

8.  [Decreased plasma carnitine in Type I diabetes mellitus].

Authors:  P Pregant; G Schernthaner; E Legenstein; L Lienhart; S Bruck; C Schnack; E Kaiser
Journal:  Klin Wochenschr       Date:  1991-08-16

9.  Levels of lipoprotein(a), apolipoprotein B, and lipoprotein cholesterol distribution in IDDM. Results from follow-up in the Diabetes Control and Complications Trial.

Authors:  J Q Purnell; S M Marcovina; J E Hokanson; H Kennedy; P A Cleary; M W Steffes; J D Brunzell
Journal:  Diabetes       Date:  1995-10       Impact factor: 9.461

10.  Plasma lipoprotein (a) concentration and phenotypes in diabetes mellitus.

Authors:  A Császár; H Dieplinger; C Sandholzer; I Karádi; E Juhász; H Drexel; T Halmos; L Romics; J R Patsch; G Utermann
Journal:  Diabetologia       Date:  1993-01       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.